Pregledni rad

Hyperhomocysteinemia and Its Treatment in Patients with Ischemic Stroke

Omer Ć. Ibrahimagić ; Univerzitetski klinički centar Tuzla
Dževdet Smajlović ; Univerzitetski klinički centar Tuzla
Zikrija Dostović ; Univerzitetski klinički centar Tuzla
Zejneba Pašić ; Univerzitetski klinički centar Tuzla
Aida Šehanović ; Univerzitetski klinički centar Tuzla
Renata Hodžić ; Univerzitetski klinički centar Tuzla

Sažetak

Homocysteine is a metabolite of methionine demethylation. It has proatherogenic, prothrombotic, prooxidative, proapoptotic, neurotoxic, neuroinflammatory and neurodegenerative effects. Hyperhomocysteinemia correlates with C667T MTHFR mutation, decreased folic acid and vitamin B levels, and prolonged use of certain medications. We measured homocysteine levels in sixty patients at the Department of Neurology of the University Clinical Centre Tuzla and monitored the effects of medicaments (folic acid, vitamin B) every six months over a three-year period. In acute phase of ischemic stroke, hyperhomocysteinemia was present in 16.67% of patients. The average level was higher in male patients (p=0.073). Higher than normal homocysteine levels were recorded in every third male patient (33.3%) (p<0.001). Hyperhomocysteinemia was not observed in women with ischemic stroke. The oral administration of 5 mg folic acid per day normalized homocysteine levels in all patients, but some also received vitamin B.

Ključne riječi

homocysteine; ischemic stroke; folic acid; vitamin B

Hrčak ID:

102979

URI

https://hrcak.srce.hr/102979

Datum izdavanja:

18.4.2013.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.811 *